DOI QR코드

DOI QR Code

Genotype Distribution of Human Papillomavirus in Women with Abnormal Cervical Cytology in an Esophageal Carcinoma High Incidence Area of China

  • Mai, Rui-Qin (Department of Laboratory Medicine, the First Affiliated Hospital of Shantou University Medical College) ;
  • Huang, Bo (Department of Pathology, Shantou University Medical College) ;
  • Shen, Ling (Department of Obstetrics and Gynecology, the First Affiliated Hospital of Shantou University Medical College) ;
  • Zhang, Guo-Hong (Department of Pathology, Shantou University Medical College) ;
  • Hong, Liang-Li (Department of Pathology, the First Affiliated Hospital of Shantou University Medical College) ;
  • Cai, Ying-Mu (Department of Laboratory Medicine, the First Affiliated Hospital of Shantou University Medical College)
  • Published : 2014.06.30

Abstract

Infection with human papillomavirus (HPV) could affect genesis of both cervical and esophageal cancers. The type-specific distribution of HPV in cervical cytology abnormalities of women has remained unclear in Shantou, an esophageal cancer high-incidence area of China. Data from 22,617 women who were subjected to cervical HPV DNA testing with simultaneous cervical cytological examination during 2009-2013 were therefore here retrospectively evaluated in a hospital-based study. Overall, 16.2% (3,584/22,114)of women with normal cytology were HR-HPV positive, with HPV-52 (4.07%) as the most common type followed by -16 (3.63%), and -58 (2.46%). Prevalence of HR-HPV was 50.3% (253/503) in women with cervical cytological abnormalities, of which in ASC-H 71.4%, ASC-US 39.1%, HSIL 80.3% and LSIL 73.7%. HPV-58 (14.12%) was the most common type for all cervical cytological abnormalities, followed by HPV-16 (13.72%), and -52 (12.72%), while the more common HPV-16 type in ASC-H (42.9%) and HSIL (36.1%), HPV-52 and -58 were the most common types for ASC-US (10.3%) and LSIL (25%), respectively. Multiple HPV co-infections were identified in 33.2% (84/253) cytology abnormalities with positive HR-HPV, and the highest prevalence of HPV-58/16 combination in HSIL (28.6%, 6/21) was observed. Our data indicated a relative high prevalence of HPV-58 and -52 in women with cervical cytological abnormalities, which should be considered in the development of next-generation vaccines for Shantou.

Keywords

References

  1. Bao YP, Li N, Smith JS, Qiao YL (2008). Human papillomavirus type distribution in women from Asia: a meta-analysis. Review of. Int J Gynecol Cancer, 18, 71-9.
  2. Chan PK (2012). Human papillomavirus type 58: the unique role in cervical cancers in East Asia. Cell Biosci, 2, 17. https://doi.org/10.1186/2045-3701-2-17
  3. Chan PK, Cheung TH, Li WH, et al (2012). Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in Southern China. Int J Cancer, 131, 692-705. https://doi.org/10.1002/ijc.26404
  4. Chan PK, Luk AC, Park JS, et al (2011). Identification of human papillomavirus type 58 lineages and the distribution worldwide. J Infect Dis, 203, 1565-73. https://doi.org/10.1093/infdis/jir157
  5. Chan PK, Zhang C, Park JS, et al (2013). Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations. Int J Cancer, 132, 2528-36. https://doi.org/10.1002/ijc.27932
  6. Chen Q (2012). Epidemiologic characterization of human papillomavirus infection in rural Chaozhou, eastern Guangdong Province of China. PLoS One, 7, e32149. https://doi.org/10.1371/journal.pone.0032149
  7. Chen Q, Luo ZY, Lin M, et al (2012). Prevalence and genotype distribution of human papillomavirus infections in women attending hospitals in Chaozhou of Guangdong province. Asian Pac J Cancer Prev, 13, 1519-24. https://doi.org/10.7314/APJCP.2012.13.4.1519
  8. Clifford GM, Gallus S, Herrero R, et al (2005). Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet, 366, 991-8. https://doi.org/10.1016/S0140-6736(05)67069-9
  9. Gage JC, Schiffman M, Solomon D, et al (2013). Risk of precancer determined by HPV genotype combinations in women with minor cytologic abnormalities. Cancer Epidemiol Biomarkers Prev, 22, 1095-101. https://doi.org/10.1158/1055-9965.EPI-12-1455
  10. Guo P, Huang ZL, Yu P, Li K (2012). Trends in cancer mortality in China: an update. Ann Oncol, 23, 2755-62. https://doi.org/10.1093/annonc/mds069
  11. Huang Y, Lin M, Luo ZY, et al (2013). Low prevalence of HPV in male sexual partners of HR-HPV infected females and low concordance of viral types in couples in Eastern Guangdong. Asian Pac J Cancer Prev, 14, 1755-60. https://doi.org/10.7314/APJCP.2013.14.3.1755
  12. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  13. Kim K, Zang R, Choi SC, Ryu SY, Kim JW (2009). Current status of gynecological cancer in China. J Gynecol Oncol, 20, 72-6. https://doi.org/10.3802/jgo.2009.20.2.72
  14. Kim MJ, Kim JJ, Kim S (2013). Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7, 014 Korean women. Obstet Gynecol Sci, 56, 110-20. https://doi.org/10.5468/OGS.2013.56.2.110
  15. Kovacic MB, Castle PE, Herrero R, et al (2006). Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res, 66, 10112-9. https://doi.org/10.1158/0008-5472.CAN-06-1812
  16. Li H, Zhang J, Chen Z, Zhou B, Tan Y (2013). Prevalence of human papillomavirus genotypes among women in Hunan province, China. Eur J Obstet Gynecol Reprod Biol, 170, 202-5. https://doi.org/10.1016/j.ejogrb.2013.05.010
  17. Li J, Kang LN, Qiao YL (2011). Review of the cervical cancer disease burden in mainland China. Asian Pac J Cancer Prev, 12, 1149-53.
  18. Li J, Mei J, Wang X, et al (2012). Human papillomavirus typespecific prevalence in women with cervical intraepithelial neoplasm in Western China. J Clin Microbiol, 50, 1079-81. https://doi.org/10.1128/JCM.06214-11
  19. Lin M, Yang LY, Li LJ, et al (2008). Genital human papillomavirus screening by gene chip in Chinese women of Guangdong province. Aust N Z J Obstet Gynaecol, 48, 189-94. https://doi.org/10.1111/j.1479-828X.2008.00844.x
  20. Liu HY, Zhou SL, Ku JW, et al (2014). Prevalence of human papillomavirus infection in esophageal and cervical cancers in the high incidence area for the two diseases from 2007 to 2009 in Linzhou of Henan Province, Northern China. Arch Virol.
  21. Munagala R, Dona MG, Rai SN, et al (2009). Significance of multiple HPV infection in cervical cancer patients and its impact on treatment response. Review of. Int J Oncol, 34, 263-71.
  22. Petrick JL, Wyss AB, Butler AM, et al (2014). Prevalence of human papillomavirus among oesophageal squamous cell carcinoma cases: systematic review and meta-analysis. Br J Cancer.
  23. Shen ZY, Hu SP, Lu LC, et al (2002). Detection of human papillomavirus in esophageal carcinoma. J Med Virol, 68, 412-6. https://doi.org/10.1002/jmv.10219
  24. Shi JF, Canfell K, Lew JB, Qiao YL (2012). The burden of cervical cancer in China: synthesis of the evidence. Int J Cancer, 130, 641-52. https://doi.org/10.1002/ijc.26042
  25. Solomon D, Davey D, Kurman R, et al (2002). The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA, 287, 2114-9. https://doi.org/10.1001/jama.287.16.2114
  26. Su M, Liu M, Tian DP, et al (2007). Temporal trends of esophageal cancer during 1995-2004 in Nanao Island, an extremely high-risk area in China. Eur J Epidemiol, 22, 43-8. https://doi.org/10.1007/s10654-006-9086-x
  27. Trottier H, Mahmud S, Costa MC, et al (2006). Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev, 15, 1274-80. https://doi.org/10.1158/1055-9965.EPI-06-0129
  28. Wang YC, Wei LJ, Liu JT, Li SX, Wang QS (2012). Comparison of cancer incidence between China and the USA. Cancer Biol Med, 9, 128-32.
  29. Wang YY, Li L, Wei S, et al (2013). Human papillomavirus (HPV) infection in women participating in cervical cancer screening from 2006 to 2010 in Shenzhen City, South China. Asian Pac J Cancer Prev, 14, 7483-7. https://doi.org/10.7314/APJCP.2013.14.12.7483
  30. Zhang D, Zhang Q, Zhou L, et al (2010). Comparison of prevalence, viral load, physical status and expression of human papillomavirus-16, -18 and -58 in esophageal and cervical cancer: a case-control study. BMC Cancer, 10, 650. https://doi.org/10.1186/1471-2407-10-650
  31. Zheng BW, Chen CD, Wei AX, and Ran H (2009). Research of cervical cytology screening in diagnosis of 370, 000 cases with cervical lesion in Guangdong. Chinese-German J Clinical Oncology, 8, 90-4. https://doi.org/10.1007/s10330-008-0126-8

Cited by

  1. Clinical Observation and Therapeutic Evaluation of Rh-endostatin Combined with DP Regimen in Treating Patients with Advanced Esophageal Cancer vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6565
  2. High-risk Human Papillomavirus Genotypes in Cervical Lesions and Vaccination Challenges in China vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2193